<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2020-2741</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2741</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БИОБАНКИРОВАНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BIOBANKING</subject></subj-group></article-categories><title-group><article-title>Работа в условиях пандемии COVID-19 – опыт биобанка ФГБУ «НМИЦ онкологии» Минздрава России</article-title><trans-title-group xml:lang="en"><trans-title>Work within the COVID-19 pandemic — the experience of the biobank of the National Medical Research Center of Oncology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8516-5415</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самохина</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Samokhina</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ирина Владимировна Самохина— младший научный сотрудник, лаборатории иммунофенотипирования</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"/><email xlink:type="simple">isam16@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0874-5261</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сагакянц</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Sagakyants</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александр Борисович Сагакянц. — кандидат биологических наук, руководитель лаборатории иммунофенотипирования </p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"/><email xlink:type="simple">asagak@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр онкологии" Минздрава России</institution></aff><aff xml:lang="en"><institution>Research Medical Center of Oncology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>24</day><month>12</month><year>2020</year></pub-date><volume>19</volume><issue>6</issue><fpage>2741</fpage><lpage>2741</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Самохина И.В., Сагакянц А.Б., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Самохина И.В., Сагакянц А.Б.</copyright-holder><copyright-holder xml:lang="en">Samokhina I.V., Sagakyants A.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2741">https://cardiovascular.elpub.ru/jour/article/view/2741</self-uri><abstract><sec><title>Цель</title><p>Цель. Представить основные результаты и характер изменения работы биобанка ФГБУ “НМИЦ онкологии” Минздрава России во время пандемии новой коронавирусной инфекции (COVID-19).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В работе представлен анализ динамики поступления свежезамороженных биообразцов прооперированных пациентов за 3 квартала 2019 и 2020гг, а также рассмотрены возможные пути реализации научно-исследовательских проектов по сбору и депонированию материалов для биобанка в условиях пандемии COVID-19. В соответствии с реализуемыми научно-исследовательскими проектами в работу были включены лица старше 18 лет с первичным характером новообразований органов желудочно-кишечного тракта, при госпитализации давшие информированное согласие о передаче биологического материала в биобанк. Одним из условий включения стало наличие отрицательного результата мазка из носоглотки на SARS-CoV-2, полученного методом полимеразной цепной реакции. Подсчет данных, сравнительный анализ результатов осуществляли с применением пакета программ Microsoft Office Excel.</p></sec><sec><title>Результаты</title><p>Результаты. При подсчете процентного соотношения депонированного материала за 2 года, выяснилось, что в 2019г за первый квартал поступило 34% биопрепаратов от общего количества за год, в 2020г — 50%. За второй квартал 2019г — 35%. Особенностью второго квартала 2020г стало изменение в графике работы учреждений в связи с пандемией COVID-19, что послужило причиной снижения количества криообразцов на 56% в сравнении с тем же периодом за 2019г. Рекордно низкий показатель соответствует 14% от общего количества собранного материала за 3 квартала 2020г. В третьем квартале 2020г поток поступившего материала был восстановлен и составил — 65 пациентов, что соответствует 36% от общего объема собираемого материала в настоящем году и на 23% больше, чем в 2019г.</p></sec><sec><title>Заключение</title><p>Заключение. За счет сложившейся ситуации, связанной с пандемией COVID-19 и острой эпидемиологической обстановкой в стране, критическое снижение количества депонированного материала во втором квартале 2020г определило необходимость адаптации существующих правил ведения отечественного биобанкирования и биобанка “НМИЦ онкологии” в частности. Возможные пути адаптации организации и проведения научно-исследовательских проектов в сложившихся условиях могут заключаться в создании совместных тематических проектов между группами ученых различных организаций с обязательным учетом требований информационной и биологической безопасности. Данная проблема и пути её решения широко обсуждались на международных и отечественных площадках, в т.ч. на 4-ом научном заседании Национальной ассоциации биобанков и специалистов по биобанкированию (НАСБИО), посвященном вопросам организации биобанкирования в период пандемии COVID-19.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To present the main results and changes in the work of the biobank of the National Medical Research Center of Oncology during the pandemic of coronavirus disease 2019 (COVID-19).</p></sec><sec><title>Material and methods</title><p>Material and methods. The paper presents a dynamic analysis of the delivery of fresh frozen biological samples from operated patients for three quarters of 2019 and 2020, as well as considers possible ways to implement research projects to collect and deposit materials for the biobank within the COVID-19 pandemic. The work included persons over 18 years old, with primary gastrointestinal cancers, who, upon hospitalization, gave informed consent to transfer biological material to</p></sec><sec><title>the biobank</title><p>the biobank. One of the inclusion criteria was the presence of a negative nasopharyngeal swabs tested for SARS-CoV-2 by the polymerase chain reaction. Data calculation and comparative analysis of the results was carried out using the Microsoft Office Excel software package.</p></sec><sec><title>Results</title><p>Results. It was revealed that in the first quarter of 2019, 34% of biological samples were received from the total amount for the year, while in 2020 — 50%; in the second quarter of 2019 — 35%. The second quarter of 2020 was characterized by change in the schedule of work of institutions due to the COVID-19 pandemic, which led to a 56% decrease in the number of samples compared to the same period in 2019 and amounted to 14% of material collected for the three quarters of2020. In the third quarter of 2020, the flow was restored and amounted to 65 patients, which corresponds to 36% of material collected in this year and is more than in 2019 by 23%.</p></sec><sec><title>Conclusion</title><p>Conclusion. a critical decrease in the deposited material in the second quarter of 2020 indicated the need to adapt the current biobanking rules inRussia in general and the studied biobank in particular. Possible adaptation ways may consist in the creation of joint projects between groups of scientists from different organizations, taking into account the requirements of information and biological safety. This problem and ways to solve it were widely discussed at international and Russian platforms, including the 4th meeting of the National Association of Biobanks and Biobanking Specialists, dedicated to the organization of biobanking during the COVID-19 pandemic.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>биобанкинг</kwd><kwd>биорепозиторий</kwd><kwd>онкология</kwd><kwd>опухоль</kwd><kwd>биоматериал</kwd><kwd>пандемия COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>желудочно-кишечный тракт</kwd></kwd-group><kwd-group xml:lang="en"><kwd>biobanking</kwd><kwd>biorepository</kwd><kwd>oncology</kwd><kwd>tumor</kwd><kwd>biomaterial</kwd><kwd>COVID-19 pandemic</kwd><kwd>SARS-CoV-2</kwd><kwd>gastrointestinal tract</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. World Health Organization, Geneva. https://www. who. int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. (11 Feb 2020)</mixed-citation><mixed-citation xml:lang="en">WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. World Health Organization, Geneva. https://www. who. int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. (11 Feb 2020)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Deshmukh V, Tripathi SC, Pandey A et al. COVID-19: a conundrum to decipher. Eur Rev Med Pharmacol Sci. 2020;24(10):5830-41. doi: 10.26355/eurrev_202005_21378</mixed-citation><mixed-citation xml:lang="en">Deshmukh V, Tripathi SC, Pandey A et al. COVID-19: a conundrum to decipher. Eur Rev Med Pharmacol Sci. 2020;24(10):5830-41. doi: 10.26355/eurrev_202005_21378</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yi Y, Lagniton PhNP, Ye S et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. International journal of biological sciences. 2020;16(10):1753-66. doi: 10.7150/ijbs.45134</mixed-citation><mixed-citation xml:lang="en">Yi Y, Lagniton PhNP, Ye S et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. International journal of biological sciences. 2020;16(10):1753-66. doi: 10.7150/ijbs.45134</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. Journal of Preventive Medicine and Public Health. 2020;53(2):70. doi: 10.3961/jpmph.20.065</mixed-citation><mixed-citation xml:lang="en">Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. Journal of Preventive Medicine and Public Health. 2020;53(2):70. doi: 10.3961/jpmph.20.065</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Khanji MY, Chahal AA, Aung N et al. COVID-19 and the UK biobank-opportunities and challenges for research and collaboration with other large population studies. Front. Cardiovasc. Med. 2020;7:156. doi.org/10.3389/fcvm.2020.00156</mixed-citation><mixed-citation xml:lang="en">Khanji MY, Chahal AA, Aung N et al. COVID-19 and the UK biobank-opportunities and challenges for research and collaboration with other large population studies. Front. Cardiovasc. Med. 2020;7:156. doi.org/10.3389/fcvm.2020.00156</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Stergachis AB, Weiss ST, Green RC. Biobanks could identify medically actionable findings relevant for COVID-19 clinical care. Nature Medicine. 2020;26(70):991. https://doi.org/10.1038/s41591-020-0953-x</mixed-citation><mixed-citation xml:lang="en">Stergachis AB, Weiss ST, Green RC. Biobanks could identify medically actionable findings relevant for COVID-19 clinical care. Nature Medicine. 2020;26(70):991. https://doi.org/10.1038/s41591-020-0953-x</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Henderson MK, Kozlakidis Z, Fachiroh J et al. The Responses of Biobanks to COVID-19. Biopreservation and Biobanking. https://doi.org/10.1089/bio.2020.29074.mkh (31 Aug 2020)</mixed-citation><mixed-citation xml:lang="en">Henderson MK, Kozlakidis Z, Fachiroh J et al. The Responses of Biobanks to COVID-19. Biopreservation and Biobanking. https://doi.org/10.1089/bio.2020.29074.mkh (31 Aug 2020)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
